Clin2
NCT06347718Possibly a fitRecruiting

Car-T cells for autoimmune disease

Systemic Lupus ErythematosusSystemic SclerosisDermatomyositisPolymyositis

Treatments studied

Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.

This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
24 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 or older.
  • You have been diagnosed with lupus, scleroderma, or myositis and have active disease despite trying at least two standard treatments.
  • Your kidneys, liver, heart, and lungs are working well enough (doctors will check).
  • You have not had prior CAR-T cell therapy or a stem cell/organ transplant.
  • You are not pregnant and will use effective birth control for 12 months after treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06685042Recruiting· Phase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases

This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.

Rome, Lazio
NCT06056921Recruiting· Phase 1
CAR T-cell therapy for hard-to-treat autoimmune diseases

This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.

Taiyuan, Shanxi
NCT06548607Recruiting· Early Phase 1
CAR-T therapy for autoimmune diseases

This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.

Bengbu, Anhui
NCT06420154Not yet recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.

Wenzhou, Zhejiang
NCT07246096Recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.

Shanghai
NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases

This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.

Nanjing, Jiangsu

Hear when a new Systemic Lupus Erythematosus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.